Objective: We aimed to investigate the role of oxidative stress in the progression of multiple sclerosis (MS).
. However, the most frequently determined F 2 -IP (8-iso-PGF 2a ), can also be generated during enzymatic oxidation of 20:4 to prostaglandin F 2a (PGF 2a ), involving cyclooxygenase. 8 As cyclooxygenase is significantly induced during inflammation, it can lead to incorrect biomarker assignment and interpretation. 8 Therefore, we quantified the ROS-derived F 2 -IP and enzymederived PGF 2a in plasma and CSF of patients with MS. We correlated these oxidation markers with disease severity, patient age, and other clinical measures. To explore whether CNS 20:4 oxidation changes with treatment, we also analyzed samples from 2 intervention studies of patients with progressive MS treated with natalizumab or methylprednisolone. 8 were from Cayman Chemicals (Ann Arbor, MI). Artificial CSF was from Tocris Bioscience (Bristol, UK). Methanol (Fisher Scientific Inc.), hexane, and ethyl acetate (Lab Scan) were of high-performance liquid chromatography grade, and Bond Elut CertifyII SPE columns were from Agilent Technologies (Santa Clara, CA). Other chemicals were from Sigma, unless indicated otherwise.
Standard protocol approvals, registrations, and patient consents. The ethical review boards of the Karolinska Institute in Sweden (DN: 2009/2107-31-2) approved the study involving 62 patients with MS with a diagnosis according to the revised McDonald criteria 9 and a heterogeneous control group of 45 individuals with other neurologic diseases (ONDs) (see the table for demographic data). These controls with ONDs displayed no clinical and neuroradiologic features of MS and no signs of intrathecal inflammation as shown by the presence of oligoclonal bands, increased immunoglobulin G index, or pleocytosis (higher than upper normal limit, i.e., .5,000 cells/mL). The ethics committee of the Capital Region of Denmark approved the 2 intervention studies with natalizumab 10 (n 5 24) and methylprednisolone 11 (n 5 30). Written informed consent was obtained from all participants. Disease severity was assessed using the Expanded Disability Status Scale score. CSF was collected during diagnostic workup according to clinical routine, 10, 11 and for the Swedish study, venous EDTA blood samples were collected at the same time. Following centrifugation (15 minutes, 2,700g, room temperature), the resulting plasma was stored at 280°C until use. CSF mononuclear and polymorphonuclear cells were determined by flow cytometry and albumin with an automated system (Beckman Coulter UniCel DxC 800 Pro). Chemokine CXCL13, matrix metalloproteinase-9, osteopontin, and neurofilament light protein were determined using corresponding ELISA kits. 12 Coded samples were shipped frozen on dry ice to Australia for liquid chromatographytandem mass spectrometric analysis of F 2 -IP and PGF 2a . Upon receipt, frozen samples were placed immediately at 280°C until analysis was performed blinded within 12 months. The Sydney Local Health District Ethics Review We first examined systemic oxidative stress in progressive MS by measuring the concentrations of 20:4, F 2 -IP, and PGF 2a in plasma of controls with OND and patients with MS at various disease stages. The method used allowed for quantification of 4 series of F 2 -IP ( figure 1A ). Because of the limited availability of authentic standards required for unambiguous assignment of chromatographic peaks, we restricted our analysis to F 2 -IP species for which standards were available commercially (figure 1B). Plasma concentrations of F 2 -IP and PGF 2a were significantly lower in patients with progressive MS compared to patients with relapsing-remitting MS (RRMS) and OND controls (figure 2). This was true for individual 5-and 15-species and for the sum of products detected for each IP series. The amount of the oxidation products formed can be affected by the concentration of substrate 13 ; however, plasma 20:4 concentrations did not vary between controls with OND and patients with MS ( figure 2G ). These results indicate that MS progression is not associated with increased systemic oxidative stress. Associations among PGF 2a , disease severity, CSF biomarkers, and age. In CSF, the concentration of PGF 2a increased with disease severity assessed by the Expanded Disability Status Scale score, irrespective of whether PGF 2a was standardized to CSF volume (r s 5 0.280, p 5 0.044) (not shown) or normalized to 20:4 (figure e-1A at Neurology.org/nn). Such association was not observed for 8-iso-15(S) PGF 2a (figure e-1B) and other F 2 -IP (not shown). In contrast to PGF 2a , none of the validated CSF biomarkers determined correlated with disease severity (figure e-1, C-I). The CSF concentration of PGF 2a (ng/mg 20:4) increased with patient age (figure e-1J), although it remained higher in progressive patients compared with age-matched controls with OND (figure e-1K). Also, CSF PGF 2a remained higher in patients with secondary progressive MS taking nonsteroidal anti-inflammatory drugs compared with OND controls (figure e-1L) . PGF 2a did not correlate significantly with any of the biomarkers determined (figure e-2).
In plasma, the content of PGF 2a and each individual F 2 -IP species decreased with increasing disease severity (figure e-3, A-F). Plasma PGF 2a decreased with patient age (figure e-3G) but it remained significantly lower in progressive patients compared with age-matched OND controls (figure e-3H). As a result, the CSF/plasma ratio of PGF 2a and F 2 -IP (except for 8-iso-15[R] PGF 2a ) were higher in patients with MS who had progressive disease compared with controls with OND ( figure e-3, I-N) , despite a decrease in the CSF/plasma ratio of 20:4 (figure e-3O). These data suggest that the disease-associated increase in CSF PGF 2a originates from increased local enzymatic oxidation of 20:4 rather than circulating PGF 2a . This interpretation is consistent with the absence of MSassociated increase in the CSF/plasma albumin ratio (figure e-3P). figure 4E ). In contrast to nonenzymatic 15(R)-PGF 2a , its corresponding stereoisomer and enzymatic product, 15(S)-PGF 2a , was significantly decreased after treatment compared with baseline (p 5 0.002; figure 4F ). CSF concentrations of 20:4 did not vary significantly between baseline and treatment (data not shown).
We repeated the above analyses in a separate set of CSF samples from patients with progressive MS at baseline and 60 weeks after treatment with methylprednisolone. 11 In this cohort of 23 patients, PGF 2a was detected in CSF samples of only 7 patients. In all of these patients, methylprednisolone treatment also significantly decreased PGF 2a (p 5 0.031) without changing the content of 20:4 (p 5 0.819). Similar to the situation with natalizumab, CSF F 2 -IPs were generally but not consistently lower at 60 weeks compared with baseline, and this did reach statistical significance only in the case of 8-iso-15(S)-PGF 2a (p 5 0.031). Together, these results suggest that enzymatic lipid oxidation in CNS of progressive MS is decreased by modulating the enzymatic activity of inflammatory cells (with methylprednisolone) or blocking their migration into the CNS (with natalizumab).
DISCUSSION There are 2 main new findings in the present study. First, compared with OND controls, the concentration of PGF 2a in CSF is elevated in participants with progressive MS, and it increases with disease progression while it is decreased by treatment with natalizumab and methylprednisolone. The disease-associated increase in PGF 2a does not simply reflect the heightened state of inflammation and breakdown of the blood-brain barrier typical of RRMS. 14 Rather, it may represent pathologic responses to CNS resident cells, as disease severity did not correlate with CSF inflammatory cells and biomarkers, or the albumin ratio. Together, the data suggest that cyclooxygenase-mediated formation of PGF 2a may have a role in the pathogenesis of progressive MS.
Second, plasma concentrations of F 2 -IP were significantly lower in patients with progressive MS than OND controls and patients with RRMS. This is consistent with progressive MS being a consequence of impaired NADPH oxidase-dependent oxidative dampening of systemic immune activation. 2, 3 A potential implication of these findings is that the use of antioxidants may be counterproductive, and that instead agents increasing NADPH oxidase activity may be worth considering.
Although not commonly recognized, our observation of increased CSF PGF 2a in patients with progressive MS is in agreement with previous reports. Thus, cyclooxygenase-2 is expressed in CD64 1 macrophages/microglia in actively demyelinating human lesions 15 and in damaged or apoptotic oligodendrocytes. 16 Cyclooxygenase-derived products in addition to PGF 2a (PGE 2 , PGI 2 , and PGD 2 ) are elevated in the CSF of patients with MS 17 and animal models of the disease. 18 Moreover, cyclooxygenase inhibition improves MS symptoms in models of the disease. 19 The synthesis of prostaglandins is complex, 20 with their biological effects mediated via specific cellular receptors. Our findings, combined with previous reports, suggest inhibition of prostaglandin synthesis or their action as a potential drug target(s) for the treatment of MS. Because selective cyclooxygenase inhibitors can have severe side effects, 21 a better understanding of the processes that link elevated CSF PGF 2a to MS is required to identify appropriate therapeutic targets to treat MS. 18 In contrast to previous reports of increased oxidative stress in patients with MS, 22, 23 we found no evidence for MS being associated with an increase in CSF F 2 -IP, considered the "gold standard" for the assessment of in vivo oxidative stress. 7 Consistent with our findings, others 24, 25 also reported no significant difference between patients with MS and controls in their CSF content of 8,12-iPF 2a -VI (5-series F 2 -IP), determined by mass spectrometry. However, an increase in the CSF concentration of 8-iso-15(S)-PGF 2a was reported in the CSF of patients with MS with F 2 -IP determined by ELISA. [26] [27] [28] We attribute these apparent discrepancies to differences in the methods used to determine F 2 -IP. It is well known that results from ELISA are not directly comparable to those determined by mass spectrometry-based assays, 29 with the former being less specific and commonly yielding higher values for 8-iso-15(S)-PGF 2a than mass spectrometry-based assays. Thus, our findings are overall consistent with the literature and strongly suggest that oxidative stress is not increased in the CSF of patients with MS, and it does not appear to have a role in disease progression. While our study did not detect an increase in CSF F 2 -IP in patients with MS, it does not exclude the possibility that localized oxidative stress and damage to brain tissue contribute to the lesions observed in patients with MS. 30 MS lesions are thought to arise as a result of the migration of immune cells through the blood-brain barrier, resulting in an inflammatory cascade that leads to myelin loss, axonal damage, and neuronal death. 31 Binding of leukocytes a4-integrin to VCAM-1 on the vascular endothelium facilitates the migration of leukocytes across the blood-brain barrier. 32 The humanized a4-integrin monoclonal antibody natalizumab blocks the recruitment of circulating immune cells to the CNS 33 and it has recently been shown to reduce intrathecal inflammation and tissue damage in patients with progressive MS. 11 The observed decrease in enzymatic and some nonenzymatic markers of 20:4 oxidation in the CSF after natalizumab treatment suggests that intrathecal pathogenic events are triggered by systemic immune cells entering the CNS and this may be amenable to treatment. Consequently, the reduced lipid oxidation following natalizumab treatment is driven by decreased intrathecal inflammation. The finding of decreased CSF PGF 2a following treatment with the glucocorticoid methylprednisolone 34 is also important since we found that treatment was associated with clinical improvement as well as improvement in magnetization transfer ratio measurements in brain MRI studies. 11 This may reflect a direct effect of methylprednisolone on the biosynthesis of PGF 2a rather than a general inhibition of intrathecal inflammation since we found little effect of monthly methylprednisolone pulse treatment on a panel of other biomarkers in progressive MS. 11 The lack of correlation between CSF PGF 2a and validated inflammatory biomarkers, and the differences in their response to treatments, further suggests that multiple pathologic mechanisms coexist in patients with MS contributing to the complexity of this disease.
Our results indicate the potential utility of CSF PGF 2a as a biomarker of progressive MS. However, the causal role of any abnormal finding in MS, such as an increase in CSF PGF 2a , will need experimental support because it can also represent events secondary to the disease process, for example a reduced level of physical activity resulting from ambulation handicap. Currently used MRI biomarkers are adequate for patients with RRMS but do not reflect the complex pathogenesis of progressive MS. Although mass spectrometry-based determination of PGF 2a is laborintense, the specificity and reproducibility of the quantitative data for the 6 prostanoids investigated (figure 1B), over several separate batches of analyses and involving 3 independent cohorts of patients from 2 different sites, cannot be achieved with other laboratory methods.
The decrease in plasma concentration of several types of F 2 -IP in patients with MS is important. If replicated, plasma F 2 -IP could serve as a more easily obtainable biomarker for progressive MS. The data are consistent with rodent studies that imply a genetic deficiency in NADPH oxidase-derived ROS to contribute to progressive MS via inadequate oxidative dampening of immune competent cells.
2,3 Thus, there is a possible role for regulation of the oxidative burst in humans, and genetic characteristics may be decisive in whether, how soon, and how serious the development of progressive MS ensues. To date, genetic studies have largely been restricted to incidence of disease, while correlation with disease severity and progression remains to be determined.
This study shows that PGF 2a is significantly increased in the CSF of patients with progressive MS and that this is associated with disease severity and amenable to treatment, but independent of age. Since PGF 2a has biological activities, such as modulation of immunologic effector cell functions 35, 36 and vasoconstriction, 37 our results warrant future studies addressing whether cyclooxygenase-derived oxidation products of 20:4, including PGF 2a , contribute to MS pathogenesis. In addition, the surprisingly low systemic concentrations of F 2 -IP deserve further attention regarding potential mechanisms of disease progression, its treatment, and in relation to their use as systemic biomarker.
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